natgillin/translations-raw huggingface dataset:
Hiv 1-inficerede voksne patienter med let til moderat nedsat nyrefunktion I studiet GS-US-292-0112 blev virkning og sikkerhed af E/C/F/TAF fastdosis kombinationstablet evalueret i et ublindet klinisk studie af 242 hiv 1-inficerede patienter med let til moderat nedsat nyrefunktion (eGFRCG: 30-69 ml/min). 
HIV-1 infected adult patients with mild to moderate renal impairment In Study GS-US-292-0112, the efficacy and safety of E/C/F/TAF FDC tablet were evaluated in an open-label clinical study of 242 HIV-1 infected, virologically suppressed patients with mild to moderate renal impairment (eGFRCG: 30-69 mL/min).
H2-antagonister må ikke tages i en behandlingsplan med to daglige doser. 
H2-antagonists should not be taken in a twice a day regimen.
Samtidig administration kan medføre signifikante fald i plasmakoncentrationerne af rilpivirin (reduceret absorption, stigning i gastrisk pH). 
Co-administration may cause significant decreases in rilpivirine plasma concentrations (reduced absorption, increase in gastric pH).
Der skal udvises forsigtighed ved brug af Odefsey, når det gives samtidig med et lægemiddel med en kendt risiko for torsades de pointes (se pkt. 
Odefsey should be used with caution when co-administered with a medicinal product with a known risk of Torsade de Pointes (see section 4.4).
Seksoghalvfjerds procent af patienterne var mænd, 82 % var sorte og 18 % var hvide. 
Seventy-six percent were male, 82% were Black and 18% were White.
Odefsey bør ikke administreres samtidigt med de følgende lægemidler, da der kan forekomme signifikante reduktioner i plasmakoncentrationen af rilpivirin (på grund af cytochrom P450 [CYP]3Aenzyminduktion eller forhøjelse af pH-værdien i ventriklen), hvilket kan resultere i tab af Odefseys terapeutiske virkning (se pkt. 
Odefsey should not be co-administered with medicinal products that can result in significant decreases in rilpivirine plasma concentrations (due to cytochrome P450 [CYP]3A enzyme induction or gastric pH increase), which may result in loss of therapeutic effect of Odefsey (see section 4.5), including:
Ved uge 96 i de respektive studier var skift til Odefsey non-inferiørt i forhold til opretholdelse af hiv 1-RNA < 50 kopier/ml sammenlignet med fortsat behandling med FTC/RPV/TDF eller på EFV/FTC/TDF. 
At Week 96, switching to Odefsey was non-inferior in maintaining HIV-1 RNA < 50 copies/mL when compared to patients who stayed on FTC/RPV/TDF or on EFV/FTC/TDF in respective studies.
Visse lægemidler må ikke administreres sammen med Odefsey (se pkt. 
Some medicinal products should not be co-administered with Odefsey (see sections 4.3 and 4.5).
Den antivirale aktivitet af tenofoviralafenamid mod isolater af hiv 1 undertype B fra laboratoriet og klinikken blev vurderet i lymfoblastoide cellelinjer, PBMC'er, primære monocyt-/makrofage celler og CD4+ T-lymfocytter. 
The antiviral activity of tenofovir alafenamide against laboratory and clinical isolates of HIV-1 subtype B was assessed in lymphoblastoid cell lines, PBMCs, primary monocyte/macrophage cells,
I de samlede fase 3-studier med behandlingsnaive patienter TMC278-C209 og TMC278-C215 var der i uge 96 en generel gennemsnitlig ændring af basal cortisol i forhold til baseline på -19,1 (-30,85;7,37) nmol/l i rilpivirin-armen og på -0,6 (-13,29; 12,17) nmol/l i efavirenz-armen. 
In the pooled Phase 3 TMC278-C209 and TMC278-C215 studies of treatment-naïve patients, at Week 96, there was an overall mean change from baseline in basal cortisol of -19.1 (-30.85; -7.37) nmol/L in the rilpivirine arm and of -0.6 (-13.29; 12.17) nmol/L in the efavirenz arm. At Week 96, the mean change from baseline in ACTH-stimulated cortisol levels was lower in the rilpivirine arm (+18.4 ± 8.36 nmol/L) than in the efavirenz arm (+54.1 ± 7.24 nmol/L).
Median hiv 1-rna i plasma var 5,0 log10 kopier/ml, og median CD4+ celletal var 255 celler/mm3. 
Median plasma HIV-1 RNA was 5.0 log10 copies/mL and median CD4+ cell count was 255 cells/mm3.
Sofosbuvir (400 mg en gang dagligt)/rilpivirin (25 mg en gang dagligt) 
Sofosbuvir (400 mg once daily)/ Rilpivirine (25 mg once daily)
HMG CO-A-REDUKTASEHÆMMERE Atorvastatin (40 mg en gang dagligt)/rilpivirin1 
HMG CO-A REDUCTASE INHIBITORS Atorvastatin (40 mg once daily)/ Rilpivirine1
Patienter, som samtidig er inficerede med hiv og HBV Sikkerheden af emtricitabin + tenofoviralafenamid i kombination med elvitegravir og cobicistat som en fastdosis kombinationstablet (elvitegravir/cobicistat/emtricitabin/tenofoviralafenamid [E/C/F/TAF]) blev evalueret hos 72 patienter med samtidig hiv/HBV-infektion, som fik behandling mod hiv i et ublindet klinisk studie (GS-US-292-1249) til og med uge 48, hvor patienterne skiftede fra et andet antiretroviralt regime (som inkluderede TDF hos 69 ud af 72 patienter) til E/C/F/TAF. 
The safety of emtricitabine + tenofovir alafenamide in combination with elvitegravir and cobicistat as a fixed-dose combination tablet (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide [E/C/F/TAF]) was evaluated in 72 HIV/HBV co-infected patients receiving treatment for HIV in an open-label clinical study (GS-US-292-1249), through Week 48, in which patients were switched from another antiretroviral regimen (which included TDF in 69 of 72 patients) to E/C/F/TAF.
Prækliniske data for rilpivirinhydrochlorid viser ingen speciel risiko for mennesker vurderet ud fra konventionelle studier af sikkerhedsfarmakologi, toksicitet efter gentagne doser, genotoksicitet, karcinogenicitet samt reproduktions- og udviklingstoksicitet. 
Non-clinical data on rilpivirine hydrochloride reveal no special hazard for humans based on studies of safety pharmacology, drug disposition, genotoxicity, carcinogenic potential, toxicity to reproduction and development.
Anormale laboratorieværdier 
Laboratory abnormalities
Regime med emtricitabin + tenofoviralafenamid 
Emtricitabine + tenofovir alafenamide regimen
Hver Odefsey tablet indeholder 200 mg metricitabin, rilpivirinhydrochlorid svarende til 25 mg rilpivirin og tenofoviralafenamidfumarat svarende til 25 mg tenofoviralafenamid. 
Each Odefsey tablet contains 200 mg of emtricitabine, rilpivirine hydrochloride equivalent to 25 mg of rilpivirine and tenofovir alafenamide fumarate equivalent to 25 mg of tenofovir alafenamide.
 Hvis De tager nogen af disse lægemidler, må De ikke tage Odefsey. 
 If you are taking any of these medicines, do not take Odefsey and tell your doctor immediately.
I studie GS-US-292-1825 blev virkning og sikkerhed af E/C/F/TAF evalueret i et ublindet klinisk studie med én behandlingsarm hos 55 hiv 1-inficerede voksne med nyresygdom i slutstadiet (eGFRCG < 15 ml/min) i kronisk hæmodialyse i mindst 6 måneder, inden de skiftede til E/C/F/TAF fastdosis kombinationstablet. 
In Study GS-US-292-1825, the efficacy and safety of E/C/F/TAF were evaluated in a single arm, open-label clinical study in which 55 HIV-1 infected adults with end stage renal disease (eGFRCG < 15 mL/min) on chronic haemodialysis for at least 6 months before switching to E/C/F/TAF FDC tablet.
CYP-enzymhæmmere 
CYP enzyme inhibitors
ANALGETIKA Paracetamol (enkelt dosis på 500 mg)/rilpivirin1 
Paracetamol (500 mg single dose)/ Rilpivirine1
Det gennemsnitlige CD4+-celletal ved baseline var 709 celler/mm3 (104-2.527). 
The mean baseline CD4+ cell count was 709 cells/mm3 (range 104-2,527).
Samtidig administration af ketoconazol forventes at øge plasmakoncentrationerne af tenofoviralafenamid (hæmning af P-gp). 
Co-administration of ketoconazole is expected to increase plasma concentrations of tenofovir alafenamide (inhibition of P-gp).
Median hiv 1-rna i plasma ved baseline var 4,8 log10 kopier/ml, og median CD4+ celletal ved baseline var 414 celler/mm3. 
The median baseline plasma HIV-1 RNA was 4.8 log10 copies/mL, and the median baseline CD4+ cell count was 414 cells/mm3.
*baseret på historiske kontroller 
Cmax: ↔* *based on historic controls
Simeprevir (150 mg en gang dagligt)/rilpivirin 
Simeprevir (150 mg once daily)/ Rilpivirine
hovedpine1,3, svimmelhed1,3 
headache1, 3, dizziness1, 3
Hiv 1-RNA < 50 kopier/ml Behandlingsforskel 
HIV-1 RNA < 50 copies/mL Treatment difference
Hiv 1-RNA ≥ 50 kopier/mld 
HIV-1 RNA ≥ 50 copies/mLd
Ætiologien anses dog for at være multifaktoriel (herunder anvendelse af kortikosteroider, alkoholforbrug, svær immunosuppression, forhøjet Body Mass Index (BMI)). 
Although the aetiology is considered to be multifactorial (including corticosteroid use, alcohol consumption, severe immunosuppression, higher body mass index), cases of osteonecrosis have been reported particularly in patients with advanced HIV disease and/or long-term exposure to CART.
Emtricitabi + tenofoviralafenamid 
Emtricitabine + tenofovir alafenamide
Rilpivirin: 
Rifampicin:
PROTONPUMPEHÆMMERE Omeprazol (20 mg en gang dagligt)/rilpivirin1 
PROTON PUMP INHIBITORS Omeprazole (20 mg once daily)/ Rilpivirine1
Ketoconazol (400 mg en gang dagligt)/rilpivirin1 
Ketoconazole (400 mg once daily)/ Rilpivirine1
Ingen virologiske data i uge 48 eller 96 vinduet Behandling afbrudt pga. bivirkninger eller død og sidste tilgængelige hiv 1-RNA < 50 kopier/ml Behandling afbrudt af andre grunde og sidste tilgængelige hiv 1-RNA < 50 kopier/mle 
Discontinued study drug due to AE or death and last available HIV-1 RNA < 50 copies/mL Discontinued study drug due to other reasons and last available HIV-1 RNA < 50 copies/mLe
Sofosbuvir/velpatasvir (400 mg/100 mg en gang dagligt)/rilpivirin2 
Sofosbuvir/Velpatasvir (400 mg/100 mg once daily)/ Rilpivirine2
Den rapporterede tidsperiode før sådanne opstår er imidlertid variabel og disse tilstande kan opstå mange måneder efter påbegyndelse af behandlingen (se pkt. 
Autoimmune disorders (such as Graves' disease and autoimmune hepatitis) have also been reported; however, the reported time to onset is more variable and these events can occur many months after initiation of treatment (see section 4.4).
Der identificeredes ingen nye sikkerhedsproblemer hos patienter med nyresygdom i slutstadiet i kronisk hæmodialyse, som fik emtricitabin + tenofoviralafenamid sammen med elvitegravir + cobicistat som en fastdosis kombinationstablet (se pkt. 
There were no new safety issues identified in patients with end stage renal disease on chronic haemodialysis receiving emtricitabine + tenofovir alafenamide, given with elvitegravir + cobicistat as a fixed-dose combination tablet (see section 5.2).
Metabolisme og ernæring Meget almindelig: 
immune reactivation syndrome1 Metabolism and nutrition disorders Very common:
Det gennemsnitlige CD4+-celletal ved baseline var 700 celler/mm3 (140-1.862). 
The mean baseline CD4+ cell count was 700 cells/mm3 (range 140-1,862).
Administration af Odefsey sammen med protonpumpehæmmere er blevet vist at nedsætte plasmakoncentrationerne af rilpivirin (grundet en stigning i gastrisk pH), hvilket potentielt kan medføre svigtende virologisk respons på Odefsey (se pkt. 
Co-administration of Odefsey with proton pump inhibitors has been observed to decrease the plasma concentrations of rilpivirine (due to an increase in gastric pH) which could potentially lead to loss of virologic response to Odefsey (see section 4.3) and possible resistance to rilpivirine and to the NNRTI class.
Sikkerheden af emtricitabin + tenofoviralafenamid blev evalueret til og med 144 uger i et ublindet klinisk studie (GS-US-292-0112), hvor 248 hiv 1-inficerede patienter, der enten var behandlingsnaive (n = 6) eller virologisk supprimerede (n = 242) med let til moderat nedsat nyrefunktion (estimeret glomerulær filtrationshastighed via Cockcroft-Gault-metoden [eGFRCG]: 30-69 ml/min) fik emtricitabin + tenofoviralafenamid i kombination med elvitegravir + cobicistat som en fastdosis kombinationstablet. 
The safety of emtricitabine + tenofovir alafenamide was evaluated through 144 weeks in an open-label clinical study (GS-US-292-0112), in which 248 HIV-1 infected patients who were either treatment-naïve (n = 6) or virologically suppressed (n = 242) with mild to moderate renal impairment (estimated glomerular filtration rate by Cockcroft-Gault method [eGFRCG]: 30-69 mL/min) received emtricitabine + tenofovir alafenamide in combination with elvitegravir + cobicistat as a fixed-dose combination tablet.
(anvendes til at forebygge og behandle mavesår, halsbrand og opstød) dexamethason (et kortikosteroid-lægemiddel, som anvendes til at behandle betændelse og undertrykke immunforsvaret), hvis det indtages gennem munden eller indsprøjtes (undtagen hvis behandlingen kun består af en enkelt dosis) produkter, der indeholder perikon (Hypericum perforatum) (et naturlægemiddel, der anvendes til depression og angst) 
omeprazole, dexlansoprazole, lansoprazole, rabeprazole, pantoprazole and esomeprazole (used to prevent and treat stomach ulcers, heartburn, acid reflux disease) dexamethasone (a corticosteroid medicine used to treat inflammation and suppress the immune system) when taken by mouth or injected (except as a single dose treatment) products that contain St. John's wort (Hypericum perforatum) (a herbal remedy used for depression and anxiety)
Sikkerheden og virkningen af E/C/F/TAF blev evalueret i det ublindede studie GS-US-292-1249 hos voksne patienter med samtidig infektion med hiv-1 og kronisk hepatitis B. 69 ud af de 72 patienter havde tidligere fået TDF-baseret antiretroviral behandling. 
In open-label Study GS-US-292-1249, the efficacy and safety of E/C/F/TAF were evaluated in adult patients co-infected with HIV-1 and chronic hepatitis B. Sixty-nine of the 72 patients were on prior TDF-containing antiretroviral therapy.
Patienterne havde en gennemsnitsalder på 45 år (23-72), 90 % var mænd, 75 % var hvide, og 19 % var sorte. 
Patients had a mean age of 45 years (range 23-72), 90% were male, 75% were White, and 19% were Black.
0 % (95 % CI: -4,8 % til 4,8 %) 
0% (95% CI: -4.8% to 4.8%)
Virologisk supprimerede hiv 1-inficerede voksne patienter Studie GS-US-366-1216, et randomiseret, dobbeltblindt studie hos virologisk supprimerede hiv 1inficerede voksne, evaluerede effekten og sikkerheden ved skift fra FTC/RVP/TDF til Odefsey. 
Virologically suppressed HIV-1 infected adult patients In Study GS-US-366-1216, the efficacy and safety of switching from FTC/RPV/TDF to Odefsey were evaluated in a randomised, double-blind study of virologically suppressed HIV-1 infected adults.
-0,3 % (95 % CI: -4,2 % til 3,7 %) 
-0.3% (95% CI: -4.2% to 3.7%)
Patienterne havde en gennemsnitsalder på 48 år (19-76), 87% var mænd, 67 % var hvide, og 27 % var sorte. 
Patients had a mean age of 48 years (range 19-76), 87% were male, 67% were White, and 27% were Black.
Kombinationen af Odefsey og disse makrolidantibiotika kan medføre et fald i plasmakoncentrationerne af rilpivirin (hæmning af CYP3A) og tenofoviralafenamid (hæmning af P-gp). 
The combination of Odefsey with these macrolide antibiotics may cause an increase in the plasma concentrations of rilpivirine (inhibition of CYP3A) and tenofovir alafenamide (inhibition of P-gp).
Det gennemsnitlige CD4+ celletal ved baseline var 664 celler/mm3 (interval: 126-1.813). 
The mean baseline CD4+ cell count was 664 cells/mm3 (range 126-1,813).
tenofoviralafenamid tenofovirdisoproxil lamivudin adefovirdipivoxil 
tenofovir alafenamide tenofovir disoproxil lamivudine adefovir dipivoxil
Sikkerheden af emtricitabin + tenofoviralafenamid blev evalueret til og med 48 uger i et ublindet klinisk studie (GS-US-292-0106), hvor 50 hiv 1-inficerede, behandlingsnaive pædiatriske patienter i alderen 12 til < 18 år fik emtricitabin + tenofoviralafenamid i kombination med elvitegravir + cobicistat som en fastdosis kombinationstablet. 
The safety of emtricitabine + tenofovir alafenamide was evaluated through 48 weeks in an open-label clinical study (GS-US-292-0106) in which 50 HIV-1 infected, treatment-naïve paediatric patients aged 12 to < 18 years received emtricitabine + tenofovir alafenamide in combination with elvitegravir + cobicistat as a fixed-dose combination tablet.
I et studie hos virologisk supprimerede patienter, der skiftede fra EFV/FTC/TDF til Odefsey (studie GS-US-366-1160), blev der observeret fald fra baseline i værdier ved faste for total-kolesterol og HDL-kolesterol i Odefsey-armen. 
In a study of virologically suppressed patients switching from EFV/FTC/TDF to Odefsey (Study GS-US-366-1160), decreases from baseline were observed in the fasting values of total cholesterol and HDL-cholesterol in the Odefsey arm; no clinically relevant changes from baseline in median fasting values for total cholesterol to HDL-cholesterol ratio, direct LDL-cholesterol or triglycerides were observed in either treatment arm at Week 96.
5 Bivirkning identificeret under sikkerhedsovervågning efter markedsføring for lægemidler indeholdende emtricitabin.. 6 Bivirkning identificeret under sikkerhedsovervågning efter markedsføring for lægemidler indeholdende tenofoviralafenamid. 
5 Adverse reaction identified through post-marketing surveillance for emtricitabine-containing products.
træthed1,3 
fatigue1, 3
Administration af Odefsey sammen med lægemidler, der inducerer CYP3A, er blevet vist at nedsætte plasmakoncentrationerne af rilpivirin, hvilket potentielt kan medføre svigtende virologisk respons på Odefsey (se pkt. 
Co-administration of Odefsey and medicinal products that induce CYP3A has been observed to decrease the plasma concentrations of rilpivirine which could potentially lead to loss of virologic response to Odefsey (see section 4.3) and possible resistance to rilpivirine and to the NNRTI class.
Antivirale midler Ledipasvir/sofosbuvir (90 mg/400 mg en gang dagligt)/ rilpivirin 
Antiviral agents Ledipasvir/Sofosbuvir (90 mg/400 mg once daily)/ Rilpivirine
Rifabutin (300 mg en gang dagligt)/rilpivirin1 
Rifabutin (300 mg once daily)/ Rilpivirine1
Indtil uge 96 havde færre patienter i rilpivirin-armen med en virusbelastning ved baseline ≤ 100.000 kopier/ml nyopstået resistens-associerede substitutioner og/eller fænotyperesistens over for rilpivirin (7/288) end patienter med en virusbelastning ved baseline > 100.000 kopier/ml (30/262). 
had emerging resistance-associated substitutions and/or phenotypic resistance to rilpivirine (7/288) than patients with baseline viral load > 100,000 copies/mL (30/262).
Samtidig administration medfører sandsynligvis et signifikant fald i plasmakoncentrationerne af tenofoviralafenamid (induktion af P-gp). 
Co-administration is likely to cause significant decreases in the plasma concentrations of tenofovir alafenamide (induction of P-gp).
Ledipasvir/sofosbuvir (90 mg/400 mg en gang dagligt)/ tenofoviralafenamid 
Ledipasvir/Sofosbuvir (90 mg/400 mg once daily)/ Tenofovir alafenamide
Imidlertid metaboliseres emtricitabin ikke signifikant af leverenzymer, så påvirkningen af nedsat leverfunktion bør være begrænset. 
The pharmacokinetics of emtricitabine have not been studied in patients with varying degrees of hepatic insufficiency; however emtricitabine is not significantly metabolised by liver enzymes, so the impact of liver impairment should be limited.
Famotidin (enkeltdosis på 40 mg taget 12 timer før rilpivirin)/ rilpivirin1 
Famotidine (40 mg single dose taken 12 hours before rilpivirine)/ Rilpivirine1
Norethindron (1 mg en gang dagligt)/rilpivirin 
Norethindrone (1 mg once daily)/ Rilpivirine
4,1 % (95 % CI: 1,6 % til 6,7 %, p < 0,001c) 
2.0% (95% CI: -0.7% to 4.7%) 4.2% (95% CI: 0.6% to 7.8%) 4.1% (95% CI: 1.6% to 6.7%, p < 0.001c)
Andelen af respondere var højere for forsøgspersoner med en virusbelastning ved baseline ≤ 100.000 kopier/ml (78,6 %, 22/28) i forhold til dem med en virusbelastning ved baseline > 100.000 kopier/ml (50,0 %, 4/8). 
(78.6%, 22/28) as compared to those with a baseline viral load > 100,000 copies/mL (50.0%, 4/8).
Famotidin (enkeltdosis på 40 mg taget 4 timer efter rilpivirin)/ rilpivirin1 
Famotidine (40 mg single dose taken 4 hours after rilpivirine)/ Rilpivirine1
Rifabutin (300 mg en gang dagligt)/rilpivirin 
Rifabutin (300 mg once daily)/ Rilpivirine
Famotidin (enkeltdosis på 40 mg taget 2 timer før rilpivirin)/ rilpivirin1 
Famotidine (40 mg single dose taken 2 hours before rilpivirine)/ Rilpivirine1
Sådan skal De tage Odefsey 
How to take Odefsey
0,7 % (95 % CI: -4,3 % til 5,8 %) 
0.7% (95% CI: -4.3% to 5.8%)
Sikkerheden af emtricitabin + tenofoviralafenamid blev evalueret til og med 48 uger i et ublindet klinisk studie med én behandlingsarm (GS-US-292-1825), hvor 55 hiv 1-inficerede patienter, der var virologisk supprimerede med nyresygdom i slutstadiet (eGFRCG < 15 ml/min) i kronisk hæmodialyse fik emtricitabin + tenofoviralafenamid i kombination med elvitegravir + cobicistat som en fastdosis kombinationstablet. 
The safety of emtricitabine + tenofovir alafenamide was evaluated through 48 weeks in a single arm, open-label clinical study (GS-US-292-1825) in which 55 virologically suppressed HIV-1 infected patients with end stage renal disease (eGFRCG < 15 mL/min) on chronic haemodialysis received emtricitabine + tenofovir alafenamide in combination with elvitegravir + cobicistat as a fixed-dose combination tablet.
Hvis De tager et syreneutraliserende middel, skal De tage det mindst 2 timer før eller mindst 4 timer efter Odefsey. 
If you are taking an antacid, take it at least 2 hours before or at least 4 hours after Odefsey.
Samtidig administration kan medføre signifikante fald i plasmakoncentrationerne af rilpivirin (induktion af CYP3A) og tenofoviralafenamid (induktion af P-gp). 
Co-administration may cause significant decreases in the plasma concentrations of rilpivirine (induction of CYP3A) and tenofovir alafenamide (induction of P-gp).
Farmakoterapeutisk klassifikation: Antiviralt middel til systemisk brug. 
Pharmacotherapeutic group: Antiviral for systemic use; antivirals for treatment of HIV infections, combinations, ATC code: J05AR19
Gennemsnitlig procentvis ændring i AUC, Cmax, Cmin 
Mean percent change in AUC,
 Hvis dette gælder for Dem, må De ikke tage Odefsey. 
 If this applies to you, do not take Odefsey and tell your doctor immediately.
S(+) metadon: AUC: ↓ 16 % Cmin: ↓ 21 % Cmax: ↓ 13 % 
AUC: ↓ 16% Cmin: ↓ 21% Cmax: ↓ 13%
Samtidig administration vil sandsynligvis medføre signifikante fald i plasmakoncentrationerne af rilpivirin (induktion af CYP3A) og tenofoviralafenamid (induktion af P-gp). 
Co-administration is likely to cause significant decreases in the plasma concentrations of rilpivirine (induction of CYP3A) and tenofovir alafenamide (induction of P-gp).
Ved uge 48 havde 81,8 % (45/55 patienter) stadig hiv 1-rna < 50 kopier/ml, efter de var skiftet til E/C/F/TAF, Der var ingen klinisk signifikante ændringer i fastende laboratorieprøver for lipider hos patienter, som skiftede. 
At Week 48, 81.8% (45/55 patients) maintained HIV-1 RNA < 50 copies/mL after switching to E/C/F/TAF.
udslæt1,3 
rash1, 3
Sofosbuvir/velpatasvir/voxilapre vir (400 mg/100 mg/100 mg + 100 mg en gang dagligt3)/ emtricitabin/rilpivirin/ tenofoviralafenamid (200 mg/25 mg/25 mg en gang dagligt) 
Sofosbuvir/Velpatasvir/Voxilaprevir (400 mg/100 mg/100 mg + 100 mg once daily)3/
AUC: ↓ 80 % Cmin: ↓ 89 % Cmax: ↓ 69 % Induktion af CYP3A 
AUC: ↓ 80% Cmin: ↓ 89% Cmax: ↓ 69%
Studie GS-US-366-1160, et randomiseret, dobbeltblindt studie hos virologisk supprimerede hiv 1-inficerede voksne, evaluerede effekten og sikkerheden ved skift fra EVF/FTC/TDF til Odefsey. 
In Study GS-US-366-1160, the efficacy and safety of switching from EFV/FTC/TDF to Odefsey were evaluated in a randomised, double-blind study of virologically suppressed HIV-1 infected adults.
• Hvis De kommer i tanker om det 12 timer eller længere efter det tidspunkt, De normalt tager 
• If you notice 12 hours or more after the time you usually take Odefsey, then do not take the missed dose.
Samtidig administration af ciclosporin forventes at øge plasmakoncentrationerne af rilpivirin (hæmning af CYP3A) og tenofoviralafenamid (hæmning af P-gp). 
Co-administration of ciclosporin is expected to increase plasma concentrations of rilpivirine (inhibition of CYP3A) and tenofovir alafenamide (inhibition of P-gp).
Samtidig administration af disse antimykotika forventes at øge plasmakoncentrationerne af rilpivirin (hæmning af CYP3A) og tenofoviralafenamid (hæmning af P-gp). 
Co-administration of these antifungal agents is expected to increase plasma concentrations of rilpivirine (inhibition of CYP3A) and tenofovir alafenamide (inhibition of P-gp).